Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.
Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.
The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.
The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
After identifying and reviewing 76 randomized trials, combination therapy with memantine and AChEIs is confirmed to have no additional benefits over monotherapy.
Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.